Trending...
- Chicago: Mayor Johnson Announces $411M Investment into Community Wealth-Building
- PUSHERMAN- – Best Feature Documentary Official Winner at NYC and London Festivals
- Fourteen-Year-Old Naperville Juvenile Charged with Possession of Loaded Semi-automatic Handgun
CHICAGO, June 22, 2025 ~ A recent study has revealed that oral semaglutide, a medication used to treat type 2 diabetes, can significantly reduce the risk of cardiovascular events by 14%. The results were presented at the American Diabetes Association's® (ADA) 85th Scientific Sessions in Chicago as a late-breaking symposium.
The study, known as the Semaglutide Cardiovascular Outcomes Trial (SOUL), focused on adults with type 2 diabetes who are at a higher risk for cardiovascular disease. It is well-known that individuals with diabetes have a 2-4 times increased risk of developing heart disease compared to those without diabetes. This risk increases with poor glycemic control and can lead to serious conditions such as heart attacks, stroke, and heart failure.
One of the major benefits of oral semaglutide is that it eliminates the need for injections, making it more convenient for patients and potentially improving adherence to treatment. This could also lead to earlier initiation of therapy and provide cardiovascular protection for patients who may have been hesitant to use injectable medications.
More on illi News
The double-blind, placebo-controlled trial included 9,650 participants aged 50 or older with type 2 diabetes and an A1C level between 6.5% and 10.0%. All participants had either known atherosclerotic cardiovascular disease or chronic kidney disease, or both. They were randomly assigned to receive either once-daily oral semaglutide or a placebo in addition to standard care.
The primary outcome of the study was major adverse cardiovascular events (MACE), which includes death from cardiovascular causes, nonfatal myocardial infarction (heart attack), or nonfatal stroke. The results showed that there was a significant reduction in MACE among those taking oral semaglutide compared to those taking the placebo. The incidence of serious adverse events was similar between the two groups.
Dr. Darren K. McGuire, lead author of the study and a professor of medicine at UT Southwestern Medical Center, emphasized the importance of addressing co-morbidities such as heart disease when treating patients with type 2 diabetes. He believes that the findings of this study suggest that oral semaglutide could be a promising option for patients in need of treatment for both diabetes and cardiovascular risk.
More on illi News
The initial results of the study were published in the New England Journal of Medicine in March, showing a 14% reduction in MACE. The new results presented at the ADA's Scientific Sessions will provide further insight into these findings.
Dr. McGuire will present the full results during a symposium presentation on Sunday, June 22 at 4:30 PM CT. The presentation is titled "Effects of Oral Semaglutide on Cardiovascular (and Other) Outcomes in People with Type 2 Diabetes at High CV Risk." The researchers also plan to implement these findings in a real-world setting to better inform clinical next steps.
This study highlights the potential benefits of oral semaglutide for individuals with type 2 diabetes who are at high risk for cardiovascular disease. It offers hope for improved outcomes and better management of this chronic condition.
The study, known as the Semaglutide Cardiovascular Outcomes Trial (SOUL), focused on adults with type 2 diabetes who are at a higher risk for cardiovascular disease. It is well-known that individuals with diabetes have a 2-4 times increased risk of developing heart disease compared to those without diabetes. This risk increases with poor glycemic control and can lead to serious conditions such as heart attacks, stroke, and heart failure.
One of the major benefits of oral semaglutide is that it eliminates the need for injections, making it more convenient for patients and potentially improving adherence to treatment. This could also lead to earlier initiation of therapy and provide cardiovascular protection for patients who may have been hesitant to use injectable medications.
More on illi News
- Red Carpet Screening of "Ghosted" Featuring Landon Brittain at the Samuel Goldwyn Theatre
- Stem Cell-Derived Islet Therapies Shown to Reduce the Need for Injectable Insulin
- Sploot Veterinary Care Brings Modern Pet Care to Forest Park with New Clinic Opening June 23, 2025
- Anti-war groups protest vs US-NATO actions in Gaza, Iran, the Global South
- Dr. Jacqueline West Honored as Best Dentist in JAX by Folio Weekly
The double-blind, placebo-controlled trial included 9,650 participants aged 50 or older with type 2 diabetes and an A1C level between 6.5% and 10.0%. All participants had either known atherosclerotic cardiovascular disease or chronic kidney disease, or both. They were randomly assigned to receive either once-daily oral semaglutide or a placebo in addition to standard care.
The primary outcome of the study was major adverse cardiovascular events (MACE), which includes death from cardiovascular causes, nonfatal myocardial infarction (heart attack), or nonfatal stroke. The results showed that there was a significant reduction in MACE among those taking oral semaglutide compared to those taking the placebo. The incidence of serious adverse events was similar between the two groups.
Dr. Darren K. McGuire, lead author of the study and a professor of medicine at UT Southwestern Medical Center, emphasized the importance of addressing co-morbidities such as heart disease when treating patients with type 2 diabetes. He believes that the findings of this study suggest that oral semaglutide could be a promising option for patients in need of treatment for both diabetes and cardiovascular risk.
More on illi News
- Naperville Police Investigate Fatal Traffic Crash at Chicago Avenue and Naper Boulevard
- The American Diabetes Association Demonstrates Its Commitment to Curbing the Obesity Epidemic with Obesity Standards of Care
- Exciting News: Pivotal Health Solutions Acquires Revolutionary Portable Parallel Bars
- Miboxer Achieved New Goal in GILE 2025
- Jeopardy!'s Ken Jennings Headlines National Mensa Event
The initial results of the study were published in the New England Journal of Medicine in March, showing a 14% reduction in MACE. The new results presented at the ADA's Scientific Sessions will provide further insight into these findings.
Dr. McGuire will present the full results during a symposium presentation on Sunday, June 22 at 4:30 PM CT. The presentation is titled "Effects of Oral Semaglutide on Cardiovascular (and Other) Outcomes in People with Type 2 Diabetes at High CV Risk." The researchers also plan to implement these findings in a real-world setting to better inform clinical next steps.
This study highlights the potential benefits of oral semaglutide for individuals with type 2 diabetes who are at high risk for cardiovascular disease. It offers hope for improved outcomes and better management of this chronic condition.
Filed Under: Business
0 Comments
Latest on illi News
- Fray Fitness and Truemed Partner to Enable HSA/FSA-Funded Fitness Equipment Purchases
- Crazy Discount Codes App Transforms Mobile Shopping With Real-Time Deals
- KPC Marketing Services Launches to Revolutionize Legal Marketing for Small and Mid-Sized Law Firms
- Sploot Vets and DeepScan Launch Exclusive Regional U.S. Partnership to Bring Breakthrough Pet DNA Test to Market
- Lifeway Foods Toasts to 40 Years of Kefir with a Celebratory Drone Show in Chicago
- Naperville: Court Grants State's Motion to Deny Pre-Trial Release for Elgin Man Accused of Attempt Murder
- Various Measures Introduced to and Approved by The Chicago City Council
- As Sober.Buzz Community Explodes It's Growth Globally it is Announcing "Spreading the Good BUZZ" Podcast Hosted by Josh Case Debuting July 7th
- Grok3 Ranks BWRCI's Quantum-Secured AI Fail-Safe Protocol Among Most Novel AI Safety Systems
- Coming Soon: The Cottages at Powell Park Offer a Rare Blend of Charm, Convenience, and Community in Raleigh
- CredHub and All County Property Management Franchise Corp. Partner to Empower Franchisees with Rental Payment Credit Reporting Solutions
- Pregis Shares 2024 Sustainability Report Highlighting Progress in Circular Product Innovation, Emissions Accountability, and Global Impact
- Initial Order Received from Vietnamese Maritime Security and Defense Services for Advanced Video Compression Solution: RMX; Stock Symbol: RMXI
- Keebos Launches New Universal Pearl Strap That Attaches to Any Phone Case
- Anova Launches Fastest CME to London Service for Financial Markets
- Nola Blue Records signs Mud Morganfield
- Work 365 Launches Certified Provider Integration (CPI) Program to Help Distributors and CSPs Navigate Microsoft's Evolving Ecosystem
- Five Aster Awards! Fusion Marketing Group Brings Home Big Wins in 2025!
- Plot Thickens: Carvana (CVNA) says my Luxe SUV CARVANA CERTIFIED Failure Car They Sold Me "Price Just Went Up!" BUYERS BEWARE - DAY 18
- Pride Takes Center Stage in Ghostlight Ensemble Theatre Co's 9th Season